upper waypoint

23andMe Profits Off Big Pharma Demand for Genetic Data

at
Save ArticleSave Article
Failed to save article

Please try again

One of the themes of the current tech boom has been big data, which promises to change everything from business to government, to medicine. 23andMe is a startup that offers genetic tests for $99. Earlier this week 23andMe struck a deal with the drug company Pfizer, which is paying an undisclosed sum to get the genetic information of 5,000 people in 23andMe's database.

Sponsored

lower waypoint
next waypoint
Cecil Williams, Legendary Pastor of Glide Church, Dies at 94State Prisons Offset New Inmate Wage Hikes by Cutting Hours for Some WorkersAllegations of Prosecutorial Bias Spark Review of Death Penalty Convictions in Alameda CountyWhy Renaming Oakland's Airport Is a Big DealNurses Warn Patient Safety at Risk as AI Use Spreads in Health CareSF Democratic Party’s Support of Unlimited Housing Could Pressure Mayoral Candidates‘Sweeps Kill’: Bay Area Homeless Advocates Weigh in on Pivotal US Supreme Court CaseSupreme Court Hears Oral Arguments in Major Homelessness CaseBay Area Indians Brace for India’s Pivotal 2024 Election: Here’s What to KnowCalifornia’s Future Educators Divided on How to Teach Reading